osteoporosis
Endocrinology · 2005–2025
49decisions
12medicines
8carried consumer input
10individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| abaloparatide First-line treatment for patients with severe established osteoporosis and very high risk of fracture. Approved TGA indication is for osteoporosis in… | Jul 2025 | Recommended with restriction | input received Healthy Bones Australia |
| teriparatide Severe established osteoporosis in postmenopausal women and primary osteoporosis in men when other agents are considered unsuitable and when there is a high… | Jul 2025 | Recommended | 1 individuals |
| denosumab Stoboclo for osteoporosis and established osteoporosis; Osenvelt for giant cell tumour of bone and bone metastases. | Nov 2025 | Recommended | none received |
| denosumab Jubbonti (60 mg): treatment of osteoporosis (BMD T-score of -2.5 or less) in patients over 70 years old, and established osteoporosis (patients who have… | Nov 2024 | Recommended | input received Medical Oncology Group · Rare Cancers Australia |
| risedronate sodium Primary prevention of fractures in patients with osteoporosis aged less than 70 years with a BMD T-score of -2.5 or less, without a history of minimal trauma… | Mar 2023 | Not recommended | input received Healthy Bones Australia |
| teriparatide Treatment of severe established osteoporosis (initial and continuing treatment) in postmenopausal women and men, and in patients with osteoporosis associated… | Nov 2023 | Recommended | none received |
| teriparatide Severe established osteoporosis (initial and continuing treatment). Treatment of osteoporosis in postmenopausal women, primary osteoporosis in men when other… | Nov 2023 | Recommended | none received |
| romosozumab Treatment of severe osteoporosis in postmenopausal women and men at high risk of fracture, in both first-line and expanded second-line settings. | Jul 2022 | Not recommended | 3 individuals Australian Menopause Society · Australian Rheumatology Association · Healthy Bones Australia · Musculoskeletal Australia |
| teriparatide Treatment of severe established osteoporosis in postmenopausal women and primary osteoporosis in men when other agents are unsuitable and there is high risk of… | Mar 2021 | Recommended with restriction | none received |
| romosozumab Treatment of severe osteoporosis in patients who have experienced a prior fracture while on anti-resorptive therapy (later-line setting). Patients must have a… | Mar 2020 | Recommended with restriction | 5 individuals |
| romosozumab Treatment of severe osteoporosis in patients who have experienced a prior fracture while on anti-resorptive therapy (later-line setting). | Jul 2019 | Not recommended | 1 individuals |
| nandrolone decanoate Treatment of osteoporosis as monotherapy where other treatments have failed, are not tolerated, or are contraindicated, with specialist advice confirming it is… | Mar 2018 | Not recommended | unclear |
| alendronic acid Treatment of osteoporosis in patients aged 70 years and above with a BMD T-score of -2.5 or less; corticosteroid-induced osteoporosis in patients with a BMD… | Jul 2016 | Recommended with restriction | none received |
| denosumab Treatment of osteoporosis in postmenopausal women, and treatment to increase bone mass in men with osteopaenia receiving androgen deprivation therapy or men… | Jul 2016 | Recommended | none received |
| strontium ranelate Treatment of severe established osteoporosis in patients unable to use other osteoporosis medications due to contraindications or intolerance. | Jul 2015 | Recommended | input received |
| strontium ranelate Treatment of severe established osteoporosis in patients unable to use other osteoporosis medications and without cardiovascular contraindications. | Nov 2015 | Not recommended | no section in document |
| denosumab Extension of listing to include male patients with osteoporosis aged 70 years or older with a Bone Mineral Density T-score of -2.5 or less, or established… | Jul 2013 | Recommended | unclear |
| risedronate sodium Treatment of osteoporosis in patients aged 70 years or older with bone mineral density T-score ≤ -2.5. | Mar 2013 | Recommended with restriction | no section in document |
| strontium ranelate Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years or older with a bone mineral density (BMD) T-score of… | Jul 2012 | Recommended with restriction | no section in document |
| denosumab Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a woman aged 70 years of age or older with a Bone Mineral Density (BMD) T-score… | Mar 2012 | Recommended with restriction | unclear |
| Zoledronic Acid Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years or older with a bone mineral density (BMD) T-score of… | Nov 2012 | Recommended with restriction | no section in document |
| zoledronic acid Extension of listing for treatment of osteoporosis in patients aged 70 years or older with a bone mineral density (BMD) T-score of -2.5 or less in the primary… | Nov 2012 | Recommended with restriction | no section in document |
| alendronate sodium Treatment of osteoporosis in patients aged 70 years and older with a bone mineral density (BMD) T-score of -2.5 or less. | Jul 2011 | Recommended with restriction | no section in document |
| alendronic acid Treatment of osteoporosis in patients aged 70 years or older with a BMD T-score of -2.5 or less | Jul 2011 | Recommended with restriction | no section in document |
| denosumab Treatment of osteoporosis in women aged 70 years or older with a BMD T-score of -3.0 or less, and treatment of established post-menopausal osteoporosis in… | Jul 2010 | Recommended with restriction | no section in document |
| Risedronate sodium Treatment of osteoporosis and Paget disease of bone. | Jul 2010 | Recommended | no section in document |
| denosumab Treatment of osteoporosis in women aged 70 years or older with BMD T-score ≤-3.0, and treatment of established post-menopausal osteoporosis in patients with… | Jul 2010 | Recommended with restriction | no section in document |
| risedronate sodium Treatment of osteoporosis (postmenopausal osteoporosis and corticosteroid-induced osteoporosis) and Paget disease of bone. | Jul 2010 | Noted | no section in document |
| zoledronic acid Extension of PBS listing to men with established osteoporosis with fractures other than hip fractures due to minimal trauma, and men aged 70 years or older… | Nov 2009 | Recommended with restriction | no section in document |
| Zoledronic acid Treatment of established osteoporosis in patients with a hip fracture due to minimal trauma; secondary prevention of osteoporotic fractures in postmenopausal… | Jul 2008 | Recommended with restriction | no section in document |
| alendronate sodium Treatment of osteoporosis in patients aged 70 years or older with a bone mineral density (BMD) T-score of -2.5 or less. | Mar 2008 | Recommended | no section in document |
| zoledronic acid Primary prevention of fractures in high-risk women aged over 70 years with BMD T-score < -3.0, and secondary prevention of fractures in post-menopausal women… | Nov 2008 | Recommended with restriction | no section in document |
| strontium ranelate Treatment as the sole PBS-subsidised antiresorptive agent for osteoporosis in a woman aged 70 years or older with a bone mineral density (BMD) T-score of -3.0… | Jul 2007 | Recommended with restriction | no section in document |
| teriparatide Treatment of osteoporosis in postmenopausal women and men at very high risk of fracture who meet certain criteria. | Jul 2007 | Not recommended | no section in document |
| strontium ranelate Treatment of osteoporosis in women aged 70 years or older with a bone mineral density (BMD) T-score of -3.0 or less, as the sole PBS-subsidised anti-resorptive… | Jul 2007 | Recommended with restriction | no section in document |
| teriparatide Treatment of osteoporosis in postmenopausal women and men at very high risk of fracture who have failed anti-resorptive therapy. | Jul 2007 | Not recommended | no section in document |
| risedronate sodium Initial treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in patients aged 70 years of age or older and with a BMD T-score of -3.0 or… | Mar 2007 | Recommended with restriction | no section in document |
| alendronate sodium, tablet Initial treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in patients aged 70 years of age or older and with a BMD T-score of -3.0 or… | Jul 2006 | Recommended with restriction | no section in document |
| Risedronate Sodium Treatment of osteoporosis, treatment of glucocorticoid-induced osteoporosis, preservation of bone mineral density in patients on long term corticosteroid… | Jul 2006 | Not recommended | no section in document |
| alendronate sodium Initial treatment of osteoporosis in patients aged 70 years or older with a BMD T-score of -3.0 or less, or with fracture due to minimal trauma. | Jul 2006 | Recommended with restriction | no section in document |
| risedronate sodium Extension to PBS listing for patients aged 75 years or more with bone mineral density (BMD) T-score of –3.0 or less and without prevalent fracture, for… | Jul 2006 | Not recommended | no section in document |
| alendronate sodium with colecalciferol Initial treatment for established osteoporosis in patients with fracture due to minimal trauma, in patients who require a supplemental intake of vitamin D.… | Mar 2006 | Recommended with restriction | no section in document |
| teriparatide Severe established vertebral osteoporosis in men and postmenopausal women who have evidence of one or more severe painful osteoporotic vertebral fracture and… | Mar 2006 | Not recommended | no section in document |
| alendronate sodium with colecalciferol Initial and continuing treatment of established osteoporosis in patients with fracture due to minimal trauma who require supplemental intake of vitamin D. | Mar 2006 | Recommended with restriction | no section in document |
| Strontium Ranelate initial and continuing treatment for the primary prevention of fractures due to osteoporosis in postmenopausal women aged 75 or greater with a BMD T-score of… | Nov 2006 | Not recommended | no section in document |
| teriparatide Treatment by a specialist/consulting physician treating osteoporosis for severe established vertebral osteoporosis in men and postmenopausal women who have… | Nov 2006 | Recommended | no section in document |
| strontium ranelate Initial and continuing treatment for the primary prevention of fractures due to osteoporosis in postmenopausal women aged 75 or greater with Bone Mineral… | Nov 2006 | Not recommended | no section in document |
| teriparatide Initial treatment for severe established osteoporosis in men and postmenopausal women with evidence of one severe painful osteoporotic vertebral fracture. | Jul 2005 | Not recommended | no section in document |
| Teriparatide osteoporosis, specifically for patients with severe (SQ3 grade) osteoporotic fractures where other agents are considered unsuitable | no section in document |
Who spoke
Healthy Bones Australia · Medical Oncology Group · Rare Cancers Australia · Australian Menopause Society · Australian Rheumatology Association · Musculoskeletal Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 8 of 16 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.